Atara biotherapeutics to participate in virtual 33rd annual roth conference

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that pascal touchon, president and chief executive officer, and aj joshi, m.d., chief medical officer, will participate in a fireside chat at the virtual 33rd annual
ATRA Ratings Summary
ATRA Quant Ranking